EUVIMEDEUVIMED entdecken
Crossref

In Vitro Evaluation of the Inhibitory Effects of Eculizumab and C1 Esterase Inhibitor on Human and Rhesus Monkey Complement

Tianyi Hu, Hao Feng, Man Zhang, Jiaxiang Du, Yahui Huang, Jiang Zhang, Song Chen, Dengke Pan, Lan Zhu, Gang Chen

Xenotransplantation · 2025-07 · 32 (4)

DOI: 10.1111/xen.70064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Xenotransplantation, online erschienen am 30.06.2025. Verfasst von Tianyi Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ T…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Complement C1 Inhibitor Protein, Complement Activation, Complement Inactivating Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Key Research and Development Program, Special Project of Sichuan Provincial Central Committee guides local science and technology development, Natural Science Foundation of Hubei Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Complement inhibitors are important therapeutic drugs after xenotransplantation. However, it is still unclear whether the commonly used clinical complement inhibitors eculizumab and C1 esterase inhibitor (C1‐INH) can effectively inhibit complement activation in nonhuman primates.

Methods

The anti‐complement activities of eculizumab and C1‐INH were evaluated using an in vitro model of normal human serum (NHS) or normal rhesus monkey serum (NRS)‐mediated complement‐dependent cytotoxicity (CDC), with an immortalized porcine aortic endothelial cell line (iPEC) as the target.

Results

Pretreatment of the NHS with various doses of eculizumab potently inhibited the cell lysis of iPECs. FACS analysis showed that eculizumab potently suppressed the deposition of C5b‐9, but not C3c and C4c, on iPECs. However, although eculizumab pretreatment of the NRS had a dose‐dependent inhibitory effect on the killing of iPECs, the effect was much weaker than that for similarly treated NHS. Pretreatment of NHS and of NRS with C1‐INH produced almost identical dose‐dependent inhibitory effects on the killing of iPECs. At the highest concentration (10 IU/mL) of C1‐INH used, the CDC was reduced by only about 75%. In addition, C1‐INH had moderate inhibitory effects on the deposition of C3c, C4c, and C5b‐9 in both humans and rhesus monkeys. When C1‐INH was given intravenously to rhesus monkeys at a dose of 17.5 IU/kg, the serum‐mediated cell lysis detected in vitro was only slightly reduced, and the maximum inhibition was about 20%.

Conclusion

The inhibitory effect of eculizumab on human complement was significantly stronger than it was on rhesus monkey complement, showing obvious species specificity. The inhibitory effect of C1‐INH on complement in humans and rhesus monkeys was similar, but a higher concentration of C1‐INH was required in monkeys to achieve a significant inhibitory effect. These results provide a reference basis for the selection of complement inhibitors after clinical or preclinical xenotransplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedComplement C1 Inhibitor ProteinComplement ActivationComplement Inactivating AgentsComplement System ProteinsAnimalsMacaca mulattaHumansSwineTransplantation, HeterologousEndothelial Cells

Stichwörter der Autor:innen

CDCcomplement inhibitorshuman serumrhesus serumxenotransplantation

Substanzen

eculizumabAntibodies, Monoclonal, HumanizedComplement C1 Inhibitor ProteinComplement Inactivating AgentsComplement System Proteins

Autor:innen und Institutionen

  • Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Tra…
  • Chengdu Clonorgan Biotechnology Co., Ltd, Chengdu, China.

Förderung

  • National Key Research and Development Program
  • Special Project of Sichuan Provincial Central Committee guides local science and technology development
  • Natural Science Foundation of Hubei Province of China
  • National Key Research and Development Program of China

Zitieren

APA

Hu, T., Feng, H., Zhang, M., Du, J., Huang, Y., Zhang, J., Chen, S., Pan, D., Zhu, L., & Chen, G. (2025). In Vitro Evaluation of the Inhibitory Effects of Eculizumab and C1 Esterase Inhibitor on Human and Rhesus Monkey Complement. Xenotransplantation, 32(4). https://doi.org/10.1111/xen.70064

Vancouver

Hu T, Feng H, Zhang M, Du J, Huang Y, Zhang J, et al. In Vitro Evaluation of the Inhibitory Effects of Eculizumab and C1 Esterase Inhibitor on Human and Rhesus Monkey Complement. Xenotransplantation. 2025;32(4). doi:10.1111/xen.70064

BibTeX
@article{Hu2025,
  author = {Hu, Tianyi and Feng, Hao and Zhang, Man and Du, Jiaxiang and Huang, Yahui and Zhang, Jiang and Chen, Song and Pan, Dengke and Zhu, Lan and Chen, Gang},
  title = {In Vitro Evaluation of the Inhibitory Effects of Eculizumab and C1 Esterase Inhibitor on Human and Rhesus Monkey Complement},
  journal = {Xenotransplantation},
  year = {2025},
  volume = {32},
  number = {4},
  doi = {10.1111/xen.70064}
}
Kostenlos starten →